SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Aldeyra Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 29, 2023 - (NASDAQ: ALDX)
Werte in diesem Artikel
NEW YORK, Aug. 29, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Aldeyra Therapeutics, Inc..
Shareholders who purchased shares of ALDX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/aldeyra-loss-submission-form/?id=45084&from=4
CLASS PERIOD: March 17, 2022 to June 20, 2023
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the ADX-2191 new drug application ("NDA") did not include adequate and well-controlled investigations and thus failed to show substantial evidence of ADX-2191's effectiveness; (ii) as a result, the FDA was unlikely to approve the ADX-2191 NDA in its current form; (iii) accordingly, the Company had overstated ADX-2191's clinical and/or commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
DEADLINE: September 29, 2023 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/aldeyra-loss-submission-form/?id=45084&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of ALDX during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is September 29, 2023. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
SOURCE The Gross Law Firm
Ausgewählte Hebelprodukte auf Aldeyra Therapeutics
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Aldeyra Therapeutics
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle Aldeyra Therapeutics Aktie News
Aldeyra Therapeutics Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Aldeyra Therapeutics nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
| Datum | Rating | Analyst | |
|---|---|---|---|
| 26.09.18 | Aldexa Therapeutics Overweight | Cantor Fitzgerald | |
| 26.01.18 | Aldexa Therapeutics Buy | Seaport Global Securities | |
| 26.09.16 | Aldexa Therapeutics Buy | H.C. Wainwright & Co. | |
| 01.07.16 | Aldexa Therapeutics Buy | Stifel, Nicolaus & Co., Inc. | |
| 01.07.15 | Aldexa Therapeutics Buy | Canaccord Adams |